33 results on '"Guifen Xu"'
Search Results
2. Rapid detection of four polycyclic aromatic hydrocarbons in drinking water by constant-wavelength synchronous fluorescence spectrometry
- Author
-
Qihong Cai, Menglin Wang, Xiaodan Zheng, Guifen Xu, Yuanping Lin, and Yaoji Tang
- Subjects
Analytical Chemistry - Abstract
Based on the advantages of the good selectivity and high sensitivity of the synchronous fluorescence method, an efficient method using constant-wavelength synchronous fluorescence spectrometry (CWSFS) for simultaneous and rapid determination of four polycyclic aromatic hydrocarbons (PAHs) (acenaphthene, phenanthrene, benzo[a]anthracene and fluoranthene) in drinking water was established in this study. When the difference in wavelength (Δλ) at 100 nm was chosen for CWSFS scanning, the synchronous fluorescence spectra of the four PAHs could be well separated with only one single scan. Different from conventional fluorescence analysis, the established method can avoid the interference among the four PAHs each other and the interference of the drinking water sample matrix, so the four PAHs in drinking water could be well distinguished and determined. The concentrations of four PAHs in the range of 0.05-100 μg/L, 0.1-400 μg/L, 0.05-100 μg/L and 0.5-2000 μg/L showed a good linear relationship with fluorescence intensity. The limits of detection were 0.0058 μg/L, 0.021 μg/L, 0.0061 μg/L and 0.056 μg/L, respectively. The recoveries were in the range of 86.55-98.74%. Overall, the established CWSFS had the characteristics of simple, rapid, sensitive and accuracy, and had been applied to the determination of the four PAHs in various drinking water with satisfactory results.
- Published
- 2022
3. Discovery of Potent and Selective Methylenephosphonic Acid CD73 Inhibitors
- Author
-
Dillon H. Miles, Nigel Walker, Manmohan Reddy Leleti, Xiaoning Zhao, Eric T. Newcomb, Kenneth V. Lawson, Jaroslaw Kalisiak, Erick Allen Lindsey, Lixia Jin, Ada Chen, Laurent Debien, Guifen Xu, Ehesan U. Sharif, Norbert Sträter, Brandon Reid Rosen, Stephen W Young, Emma Scaletti, and Jay P. Powers
- Subjects
Adenosine ,Phosphorous Acids ,Drug Evaluation, Preclinical ,Molecular Dynamics Simulation ,Crystallography, X-Ray ,GPI-Linked Proteins ,01 natural sciences ,Structure-Activity Relationship ,03 medical and health sciences ,Immune system ,ATP hydrolysis ,Drug Discovery ,medicine ,Extracellular ,Humans ,Ectonucleotidase ,5'-Nucleotidase ,030304 developmental biology ,chemistry.chemical_classification ,0303 health sciences ,Tumor microenvironment ,Binding Sites ,Adenosine receptor ,0104 chemical sciences ,010404 medicinal & biomolecular chemistry ,Enzyme ,chemistry ,Biochemistry ,Drug Design ,Molecular Medicine ,medicine.drug - Abstract
Solid tumors are often associated with high levels of extracellular ATP. Ectonucleotidases catalyze the sequential hydrolysis of ATP to adenosine, which potently suppresses T-cell and NK-cell functions via the adenosine receptors (A2a and A2b). The ectonucleotidase CD73 catalyzes the conversion of AMP to adenosine. Thus, increased CD73 enzymatic activity in the tumor microenvironment is a potential mechanism for tumor immune evasion and has been associated with poor prognosis in the clinic. CD73 inhibition is anticipated to restore immune function by skirting this major mechanism of adenosine generation. We have developed a series of potent and selective methylenephosphonic acid CD73 inhibitors via a structure-based design. Key binding interactions of the known inhibitor adenosine-5'-(α,β-methylene)diphosphate (AMPCP) with hCD73 provided the foundation for our early designs. The structure-activity relationship study guided by this structure-based design led to the discovery of 4a, which exhibits excellent potency against CD73, exquisite selectivity against related ectonucleotidases, and a favorable pharmacokinetic profile.
- Published
- 2021
- Full Text
- View/download PDF
4. Discovery of AB680: A Potent and Selective Inhibitor of CD73
- Author
-
Brandon Reid Rosen, Manmohan Reddy Leleti, Ada Chen, Sharon Zhao, Jenna L. Jeffrey, Norbert Sträter, Eric T. Newcomb, Jay P. Powers, Kenneth V. Lawson, Lijuan Fu, Dillon H. Miles, Uli Schindler, Wade Berry, Stephen W Young, Tim Park, Emma Scaletti, Lixia Jin, Joanne B.L. Tan, Ehesan U. Sharif, Laurent Debien, Erick Allen Lindsey, Jaroslaw Kalisiak, Susanne Moschütz, Matthew J. Walters, Guifen Xu, and Nigel Walker
- Subjects
Models, Molecular ,T cell ,CD8-Positive T-Lymphocytes ,Pharmacology ,GPI-Linked Proteins ,01 natural sciences ,Small Molecule Libraries ,Mice ,Structure-Activity Relationship ,03 medical and health sciences ,Immune system ,Pharmacokinetics ,Drug Discovery ,medicine ,Extracellular ,Animals ,Humans ,Structure–activity relationship ,5'-Nucleotidase ,030304 developmental biology ,0303 health sciences ,Tumor microenvironment ,Binding Sites ,Chemistry ,Catabolism ,Haplorhini ,Adenosine ,Rats ,0104 chemical sciences ,010404 medicinal & biomolecular chemistry ,medicine.anatomical_structure ,Leukocytes, Mononuclear ,Molecular Medicine ,Protein Binding ,medicine.drug - Abstract
Extracellular adenosine (ADO), present in high concentrations in the tumor microenvironment (TME), suppresses immune function via inhibition of T cell and NK cell activation. Intratumoral generation of ADO depends on the sequential catabolism of ATP by two ecto-nucleotidases, CD39 (ATP → AMP) and CD73 (AMP → ADO). Inhibition of CD73 eliminates a major pathway of ADO production in the TME and can reverse ADO-mediated immune suppression. Extensive interrogation of structure-activity relationships (SARs), structure-based drug design, and optimization of pharmacokinetic properties culminated in the discovery of AB680, a highly potent (Ki = 5 pM), reversible, and selective inhibitor of CD73. AB680 is further characterized by very low clearance and long half-lives across preclinical species, resulting in a PK profile suitable for long-acting parenteral administration. AB680 is currently being evaluated in phase 1 clinical trials. Initial data show AB680 is well tolerated and exhibits a pharmacokinetic profile suitable for biweekly (Q2W) iv-administration in human.
- Published
- 2020
- Full Text
- View/download PDF
5. DFT exploration of sensor performances of pristine and metal-doped graphdiyne monolayer to acetaminophen drug in terms of charge transfer and bandgap changes
- Author
-
Hang Zhu, Beidou Zhou, Guifen Xu, Xianmin Fu, and Ali Mohamadi
- Subjects
Adsorption ,Aqueous solution ,Chemistry ,Band gap ,Electrical resistivity and conductivity ,Monolayer ,Analytical chemistry ,Solvation ,Charge (physics) ,Substrate (electronics) ,Physical and Theoretical Chemistry ,Condensed Matter Physics ,Biochemistry - Abstract
In order to study the electronic identity of pristine graphdiyne (GDY) as well as Zinc-doped graphdiyne (ZnGDY), first-principles calculations were done. Main parameters were investigated to analyze the adsorption behavior of acetaminophen (ACE) on the GDY and Zn GDY substrates, including the energy of adsorption, charge transfer along with the shift in the energy gap. The pristine DY sheet showed a weak attraction toward the ACE adsorbate. Additionally, the ACE adsorption onto GDY resulted in a negligible band gap energy shift of about 5.65%. On the contrary, in the gas phase, ZnGDY is mainly affected by the ACE adsorption with the adsorption energy of about 13.65. In addition, the ACE adsorption energy over the Zn-doped sheet was obtained to be 26.76 kcal/mol in the aqueous medium. A mild water solubility of ACE was reported regarding the moderate value of the calculated solvation energy. Noticeable charge transfer occurred during the ACE adsorption onto the ZnGDY substrate compared to the pristine GDY. Finally, the Zn addition resulted in an enhanced tendency toward ACE and the electrical conductivity was shifted by 13.92%, which is required for the sensory role of an adsorbent toward the ACE drug species.
- Published
- 2021
- Full Text
- View/download PDF
6. Establishment and assessment of a nomogram model for predicting the risk of fulminant myocarditis
- Author
-
Wei Zhuang, Yong Zheng, Wenxiang Zhao, Guifen Xu, Fuling Yu, and Feizhen Chen
- Subjects
Adult ,Male ,medicine.medical_specialty ,Myocarditis ,Heart Ventricles ,Fulminant ,Observational Study ,fulminant myocarditis ,Risk Assessment ,Blood Urea Nitrogen ,03 medical and health sciences ,0302 clinical medicine ,Predictive Value of Tests ,Risk Factors ,Internal medicine ,Odds Ratio ,medicine ,Humans ,Arterial Pressure ,Aspartate Aminotransferases ,030212 general & internal medicine ,Retrospective Studies ,business.industry ,nomogram model ,Troponin I ,Confounding ,Retrospective cohort study ,prediction ,General Medicine ,Odds ratio ,Middle Aged ,Nomogram ,medicine.disease ,Confidence interval ,Nomograms ,Cross-Sectional Studies ,ROC Curve ,risk factor ,Area Under Curve ,Creatinine ,030220 oncology & carcinogenesis ,Predictive value of tests ,Cardiology ,Female ,business ,Research Article - Abstract
We aimed to identify potential clinical predictors associated with the risk of fulminant myocarditis, and further to establish and assess a nomogram model based on significant attributes for clinical practicability. This is a retrospective, cross-sectional study, involving 28 patients with fulminant myocarditis and 35 age-, and sex-matched patients with non-fulminant myocarditis. Effect-size estimates are expressed as odds ratio (OR) and 95% confidence interval (CI). Fifteen factors were primarily identified to be associated with the significant risk of fulminant myocarditis after adjusting for confounders. Due to strong correlation, 6 factors were retained, including mean arterial pressure (OR, 95% CI, P: .82, .72–.94, .005), creatinine (2.15, 1.13–4.10, 0.020), blood urea nitrogen (1.45, 1.04–2.02, 0.028), aspartate aminotransferase (2.62, 1.16–5.91, 0.021), troponin I (1.43, 1.07–1.90, 0.015), and ventricular wall motion abnormality (25.81, 2.52–264.69, 0.006). The contribution of the 6 significant factors to predicting fulminant myocarditis risk was significant from multi-angle analyses, and regressing these factors in a nomogram model exhibited good predictive accuracy, as reflected by both C-index (>90%, P
- Published
- 2021
- Full Text
- View/download PDF
7. Determinants of consumer’s intention to purchase authentic green furniture
- Author
-
Yannong Hua, Xiaoping Xu, Shanyong Wang, and Guifen Xu
- Subjects
Economics and Econometrics ,Subjective norm ,Control (management) ,Perspective (graphical) ,0211 other engineering and technologies ,Theory of planned behavior ,Physical health ,Advertising ,02 engineering and technology ,010501 environmental sciences ,01 natural sciences ,Counterfeit ,Survey data collection ,Environmental consciousness ,021108 energy ,Business ,Waste Management and Disposal ,0105 earth and related environmental sciences - Abstract
Green furniture has aroused the concerns of consumers. However, the current furniture market is full of counterfeit green furniture, which affects the flourish of authentic green furniture. From the perspective of consumers, this research aims to examine the determinants of consumer’s intention to purchase authentic green furniture. Theory of planned behavior model is selected as the basic theoretical model in this research and it has been adapted by adding three variables, namely physical health concern, environmental consciousness and past experience. Based on the survey data of 451 consumers, this research finds that perceived behavioral control exerts a significant and positive effect on consumer’s intention to purchase authentic green furniture, while attitude and subjective norm have no significant influence on purchase intention. As for the new added variables, physical health concern and past experience are significantly and positively associated with consumer’s intention to purchase authentic green furniture while environmental consciousness has no significant and direct effect on purchase intention. Furthermore, it is worth noting that environmental consciousness can exert an indirect effect on purchase intention via perceived behavioral control. On the basis of research findings, relevant recommendations to promote consumers to purchase authentic green furniture have been proposed.
- Published
- 2020
- Full Text
- View/download PDF
8. A Selective Prostaglandin E2 Receptor Subtype 2 (EP2) Antagonist Increases the Macrophage-Mediated Clearance of Amyloid-Beta Plaques
- Author
-
Hannah Dou, Songli Wang, Hilary Plake Beck, Hantao Liu, Steven H. Olson, Toni Williamson, Philip Roveto, James J. S. Treanor, Frank Kayser, Guifen Xu, Ji Ma, Brian M. Fox, Qingwen Cheng, and Lixia Jin
- Subjects
Pyridones ,Amyloid beta ,medicine.medical_treatment ,Prostaglandin E2 receptor ,Plaque, Amyloid ,Pharmacology ,Rats, Sprague-Dawley ,Mice ,Structure-Activity Relationship ,Phagocytosis ,Drug Discovery ,medicine ,Animals ,Structure–activity relationship ,Tissue Distribution ,Receptor ,Molecular Structure ,biology ,CYP3A4 ,Chemistry ,Macrophages ,Antagonist ,Brain ,Receptors, Prostaglandin E, EP2 Subtype ,Rats ,Mice, Inbred C57BL ,Oxazepines ,Microsomes, Liver ,biology.protein ,Molecular Medicine ,Biological Assay ,Ex vivo ,Prostaglandin E - Abstract
A high-throughput screen resulted in the discovery of benzoxazepine 1, an EP2 antagonist possessing low microsomal stability and potent CYP3A4 inhibition. Modular optimization of lead compound 1 resulted in the discovery of benzoxazepine 52, a molecule with single-digit nM binding affinity for the EP2 receptor and significantly improved microsomal stability. It was devoid of CYP inhibition and was ∼4000-fold selective against the other EP receptors. Compound 52 was shown to have good PK properties in CD-1 mice and high CNS permeability in C57Bl/6s mice and Sprague-Dawley rats. In an ex vivo assay, it demonstrated the ability to increase the macrophage-mediated clearance of amyloid-beta plaques from brain slices in a dose-dependent manner.
- Published
- 2015
- Full Text
- View/download PDF
9. Pharmacokinetics and metabolism of AMG 232, a novel orally bioavailable inhibitor of the MDM2–p53 interaction, in rats, dogs and monkeys:in vitro–in vivocorrelation
- Author
-
Guifen Xu, Daqing Sun, Wotang T Huang, Yun Ling, Bradley K. Wong, Min Jiang, Lixia Jin, Xuelei Yan, Steven H. Olson, and Qiuping Ye
- Subjects
Male ,Health, Toxicology and Mutagenesis ,Metabolite ,Administration, Oral ,Biological Availability ,Acetates ,Pharmacology ,Toxicology ,Biochemistry ,Rats, Sprague-Dawley ,Mice ,chemistry.chemical_compound ,Dogs ,Glucuronides ,Species Specificity ,Pharmacokinetics ,In vivo ,medicine ,Animals ,Bile ,Humans ,Protein Kinase Inhibitors ,Biotransformation ,Piperidones ,Chemistry ,Haplorhini ,General Medicine ,Metabolism ,In vitro ,Rats ,Bioavailability ,medicine.anatomical_structure ,Hepatocyte ,Hepatocytes ,Microsomes, Liver ,Administration, Intravenous ,Drug metabolism - Abstract
1. AMG 232 is a novel inhibitor of the p53-MDM2 protein-protein interaction currently in Phase I clinical trials for multiple tumor indications. The objectives of the investigations reported in this article were to characterize the pharmacokinetic and drug metabolism properties of AMG 232 in pre-clinical species in vivo and in vitro, and in humans in vitro, and to predict its pharmacokinetics in humans through integrating PKDM data. 2. AMG 232 exhibited low clearance (0.25 × Qh) and moderate to high oral bioavailability in mice, rats and monkeys (42%), but high clearance (0.74 × Qh) and low oral exposure in dogs (18%). 3. Biotransformation was the major route of elimination of AMG 232 in rats, with only 7% of intravenously administered (14)C-labeled AMG 232 recovered as parent molecule in bile. The major metabolite was an acyl glucuronide as measured by in vivo rat studies and in vitro hepatocyte incubations in multiple species. 4. The in vitro-in vivo correlation of AMG 232 clearance was within 2-fold in pre-clinical species using hepatocytes. AMG 232 was predicted to exhibit low clearance, high volume distribution and long half-life in humans. The predictions are consistent with the preliminary human pharmacokinetic parameters of AMG 232 in clinical trials.
- Published
- 2015
- Full Text
- View/download PDF
10. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two
- Author
-
Casey Ager, Matthew Reilley, Courtney Nicholas, Todd Bartkowiak, Ashvin Jaiswal, Michael Curran, Tina C. Albershardt, Anshika Bajaj, Jacob F. Archer, Rebecca S. Reeves, Lisa Y. Ngo, Peter Berglund, Jan ter Meulen, Caroline Denis, Hormas Ghadially, Thomas Arnoux, Fabien Chanuc, Nicolas Fuseri, Robert W. Wilkinson, Nicolai Wagtmann, Yannis Morel, Pascale Andre, Michael B. Atkins, Matteo S. Carlino, Antoni Ribas, John A. Thompson, Toni K. Choueiri, F. Stephen Hodi, Wen-Jen Hwu, David F. McDermott, Victoria Atkinson, Jonathan S. Cebon, Bernie Fitzharris, Michael B. Jameson, Catriona McNeil, Andrew G. Hill, Eric Mangin, Malidi Ahamadi, Marianne van Vugt, Mariëlle van Zutphen, Nageatte Ibrahim, Georgina V. Long, Robyn Gartrell, Zoe Blake, Ines Simoes, Yichun Fu, Takuro Saito, Yingzhi Qian, Yan Lu, Yvonne M. Saenger, Sadna Budhu, Olivier De Henau, Roberta Zappasodi, Kyle Schlunegger, Bruce Freimark, Jeff Hutchins, Christopher A. Barker, Jedd D. Wolchok, Taha Merghoub, Elena Burova, Omaira Allbritton, Peter Hong, Jie Dai, Jerry Pei, Matt Liu, Joel Kantrowitz, Venus Lai, William Poueymirou, Douglas MacDonald, Ella Ioffe, Markus Mohrs, William Olson, Gavin Thurston, Cristian Capasso, Federica Frascaro, Sara Carpi, Siri Tähtinen, Sara Feola, Manlio Fusciello, Karita Peltonen, Beatriz Martins, Madeleine Sjöberg, Sari Pesonen, Tuuli Ranki, Lukasz Kyruk, Erkko Ylösmäki, Vincenzo Cerullo, Fabio Cerignoli, Biao Xi, Garret Guenther, Naichen Yu, Lincoln Muir, Leyna Zhao, Yama Abassi, Víctor Cervera-Carrascón, Mikko Siurala, João Santos, Riikka Havunen, Suvi Parviainen, Akseli Hemminki, Angus Dalgleish, Satvinder Mudan, Mark DeBenedette, Ana Plachco, Alicia Gamble, Elizabeth W. Grogan, John Krisko, Irina Tcherepanova, Charles Nicolette, Pooja Dhupkar, Ling Yu, Eugenie S. Kleinerman, Nancy Gordon, Italia Grenga, Lauren Lepone, Sofia Gameiro, Karin M. Knudson, Massimo Fantini, Kwong Tsang, James Hodge, Renee Donahue, Jeffrey Schlom, Elizabeth Evans, Holm Bussler, Crystal Mallow, Christine Reilly, Sebold Torno, Maria Scrivens, Cathie Foster, Alan Howell, Leslie Balch, Alyssa Knapp, John E. Leonard, Mark Paris, Terry Fisher, Siwen Hu-Lieskovan, Ernest Smith, Maurice Zauderer, William Fogler, Marilyn Franklin, Matt Thayer, Dan Saims, John L. Magnani, Jian Gong, Michael Gray, George Fromm, Suresh de Silva, Louise Giffin, Xin Xu, Jason Rose, Taylor H. Schreiber, Sofia R. Gameiro, Paul E. Clavijo, Clint T. Allen, James W. Hodge, Kwong Y. Tsang, Jane Grogan, Nicholas Manieri, Eugene Chiang, Patrick Caplazi, Mahesh Yadav, Patrick Hagner, Hsiling Chiu, Michelle Waldman, Anke Klippel, Anjan Thakurta, Michael Pourdehnad, Anita Gandhi, Ian Henrich, Laura Quick, Rob Young, Margaret Chou, Andrew Hotson, Stephen Willingham, Po Ho, Carmen Choy, Ginna Laport, Ian McCaffery, Richard Miller, Kimberly A. Tipton, Kenneth R. Wong, Victoria Singson, Chihunt Wong, Chanty Chan, Yuanhiu Huang, Shouchun Liu, Jennifer H. Richardson, W. Michael Kavanaugh, James West, Bryan A. Irving, Ritika Jaini, Matthew Loya, Charis Eng, Melissa L. Johnson, Alex A. Adjei, Mateusz Opyrchal, Suresh Ramalingam, Pasi A. Janne, George Dominguez, Dmitry Gabrilovich, Laura de Leon, Jeannette Hasapidis, Scott J. Diede, Peter Ordentlich, Scott Cruickshank, Michael L. Meyers, Matthew D. Hellmann, Pawel Kalinski, Amer Zureikat, Robert Edwards, Ravi Muthuswamy, Nataša Obermajer, Julie Urban, Lisa H. Butterfield, William Gooding, Herbert Zeh, David Bartlett, Olga Zubkova, Larissa Agapova, Marina Kapralova, Liudmila Krasovskaia, Armen Ovsepyan, Maxim Lykov, Artem Eremeev, Vladimir Bokovanov, Olga Grigoryeva, Andrey Karpov, Sergey Ruchko, Alexandr Shuster, Danny N. Khalil, Luis Felipe Campesato, Yanyun Li, Adam S. Lazorchak, Troy D. Patterson, Yueyun Ding, Pottayil Sasikumar, Naremaddepalli Sudarshan, Nagaraj Gowda, Raghuveer Ramachandra, Dodheri Samiulla, Sanjeev Giri, Rajesh Eswarappa, Murali Ramachandra, David Tuck, Timothy Wyant, Jasmin Leshem, Xiu-fen Liu, Tapan Bera, Masaki Terabe, Birgit Bossenmaier, Gerhard Niederfellner, Yoram Reiter, Ira Pastan, Leiming Xia, Yang Xia, Yangyang Hu, Yi Wang, Yangyi Bao, Fu Dai, Shiang Huang, Elaine Hurt, Robert E. Hollingsworth, Lawrence G. Lum, Alfred E. Chang, Max S. Wicha, Qiao Li, Thomas Mace, Neil Makhijani, Erin Talbert, Gregory Young, Denis Guttridge, Darwin Conwell, Gregory B. Lesinski, Rodney JM Macedo Gonzales, Austin P. Huffman, Ximi K. Wang, Ran Reshef, Andy MacKinnon, Jason Chen, Matt Gross, Gisele Marguier, Peter Shwonek, Natalija Sotirovska, Susanne Steggerda, Francesco Parlati, Amani Makkouk, Mark K. Bennett, Ethan Emberley, Tony Huang, Weiqun Li, Silinda Neou, Alison Pan, Jing Zhang, Winter Zhang, Netonia Marshall, Thomas U. Marron, Judith Agudo, Brian Brown, Joshua Brody, Christopher McQuinn, Matthew Farren, Hannah Komar, Reena Shakya, Thomas Ludwug, Y. Maurice Morillon, Scott A. Hammond, John W. Greiner, Pulak R. Nath, Anthony L. Schwartz, Dragan Maric, David D. Roberts, Aung Naing, Kyriakos P. Papadopoulos, Karen A. Autio, Deborah J. Wong, Manish Patel, Gerald Falchook, Shubham Pant, Patrick A. Ott, Melinda Whiteside, Amita Patnaik, John Mumm, Filip Janku, Ivan Chan, Todd Bauer, Rivka Colen, Peter VanVlasselaer, Gail L. Brown, Nizar M. Tannir, Martin Oft, Jeffrey Infante, Evan Lipson, Ajay Gopal, Sattva S. Neelapu, Philippe Armand, Stephen Spurgeon, John P. Leonard, Rachel E. Sanborn, Ignacio Melero, Thomas F. Gajewski, Matthew Maurer, Serena Perna, Andres A. Gutierrez, Raphael Clynes, Priyam Mitra, Satyendra Suryawanshi, Douglas Gladstone, Margaret K. Callahan, James Crooks, Sheila Brown, Audrey Gauthier, Marc Hillairet de Boisferon, Andrew MacDonald, Laura Rosa Brunet, William T. Rothwell, Peter Bell, James M. Wilson, Fumi Sato-Kaneko, Shiyin Yao, Shannon S. Zhang, Dennis A. Carson, Cristina Guiducci, Robert L. Coffman, Kazutaka Kitaura, Takaji Matsutani, Ryuji Suzuki, Tomoko Hayashi, Ezra E. W. Cohen, David Schaer, Yanxia Li, Julie Dobkin, Michael Amatulli, Gerald Hall, Thompson Doman, Jason Manro, Frank Charles Dorsey, Lillian Sams, Rikke Holmgaard, Krishnadatt Persaud, Dale Ludwig, David Surguladze, John S. Kauh, Ruslan Novosiadly, Michael Kalos, Kyla Driscoll, Hardev Pandha, Christy Ralph, Kevin Harrington, Brendan Curti, Wallace Akerley, Sumati Gupta, Alan Melcher, David Mansfield, David R. Kaufman, Emmett Schmidt, Mark Grose, Bronwyn Davies, Roberta Karpathy, Darren Shafren, Katerina Shamalov, Cyrille Cohen, Naveen Sharma, James Allison, Tala Shekarian, Sandrine Valsesia-Wittmann, Christophe Caux, Aurelien Marabelle, Brian M. Slomovitz, Kathleen M. Moore, Hagop Youssoufian, Marshall Posner, Poonam Tewary, Alan D. Brooks, Ya-Ming Xu, Kithsiri Wijeratne, Leslie A. A. Gunatilaka, Thomas J. Sayers, John P. Vasilakos, Tesha Alston, Simon Dovedi, James Elvecrog, Iwen Grigsby, Ronald Herbst, Karen Johnson, Craig Moeckly, Stefanie Mullins, Kristen Siebenaler, Julius SternJohn, Ashenafi Tilahun, Mark A. Tomai, Katharina Vogel, Eveline E. Vietsch, Anton Wellstein, Martin Wythes, Stefano Crosignani, Joseph Tumang, Shilpa Alekar, Patrick Bingham, Sandra Cauwenberghs, Jenny Chaplin, Deepak Dalvie, Sofie Denies, Coraline De Maeseneire, JunLi Feng, Kim Frederix, Samantha Greasley, Jie Guo, James Hardwick, Stephen Kaiser, Katti Jessen, Erick Kindt, Marie-Claire Letellier, Wenlin Li, Karen Maegley, Reece Marillier, Nichol Miller, Brion Murray, Romain Pirson, Julie Preillon, Virginie Rabolli, Chad Ray, Kevin Ryan, Stephanie Scales, Jay Srirangam, Jim Solowiej, Al Stewart, Nicole Streiner, Vince Torti, Konstantinos Tsaparikos, Xianxian Zheng, Gregory Driessens, Bruno Gomes, Manfred Kraus, Chunxiao Xu, Yanping Zhang, Giorgio Kradjian, Guozhong Qin, Jin Qi, Xiaomei Xu, Bo Marelli, Huakui Yu, Wilson Guzman, Rober Tighe, Rachel Salazar, Kin-Ming Lo, Jessie English, Laszlo Radvanyi, Yan Lan, Michael Postow, Yasin Senbabaoglu, Billel Gasmi, Hong Zhong, Cailian Liu, Daniel Hirschhorhn-Cymerman, Yuanyuan Zha, Gregory Malnassy, Noreen Fulton, Jae-Hyun Park, Wendy Stock, Yusuke Nakamura, Hongtao Liu, Xiaoming Ju, Rachelle Kosoff, Kimberly Ramos, Brandon Coder, Robert Petit, Michael Princiotta, Kyle Perry, Jun Zou, Ainhoa Arina, Christian Fernandez, Wenxin Zheng, Michael A. Beckett, Helena J. Mauceri, Yang-Xin Fu, Ralph R. Weichselbaum, Whitney Lewis, Yanyan Han, Yeting Wu, Chou Yang, Jing Huang, Dongyun Wu, Jin Li, Xiaoling Liang, Xiangjun Zhou, Jinlin Hou, Raffit Hassan, Thierry Jahan, Scott J. Antonia, Hedy L. Kindler, Evan W. Alley, Somayeh Honarmand, Weiqun Liu, Meredith L. Leong, Chan C. Whiting, Nitya Nair, Amanda Enstrom, Edward E. Lemmens, Takahiro Tsujikawa, Sushil Kumar, Lisa M. Coussens, Aimee L. Murphy, Dirk G. Brockstedt, Sven D. Koch, Martin Sebastian, Christian Weiss, Martin Früh, Miklos Pless, Richard Cathomas, Wolfgang Hilbe, Georg Pall, Thomas Wehler, Jürgen Alt, Helge Bischoff, Michael Geissler, Frank Griesinger, Jens Kollmeier, Alexandros Papachristofilou, Fatma Doener, Mariola Fotin-Mleczek, Madeleine Hipp, Henoch S. Hong, Karl-Josef Kallen, Ute Klinkhardt, Claudia Stosnach, Birgit Scheel, Andreas Schroeder, Tobias Seibel, Ulrike Gnad-Vogt, Alfred Zippelius, Ha-Ram Park, Yong-Oon Ahn, Tae Min Kim, Soyeon Kim, Seulki Kim, Yu Soo Lee, Bhumsuk Keam, Dong-Wan Kim, Dae Seog Heo, Shari Pilon-Thomas, Amy Weber, Jennifer Morse, Krithika Kodumudi, Hao Liu, John Mullinax, Amod A. Sarnaik, Luke Pike, Andrew Bang, Tracy Balboni, Allison Taylor, Alexander Spektor, Tyler Wilhite, Monica Krishnan, Daniel Cagney, Brian Alexander, Ayal Aizer, Elizabeth Buchbinder, Mark Awad, Leena Ghandi, Jonathan Schoenfeld, Elizabeth Lessey-Morillon, Lisa Ridnour, Neil H. Segal, Manish Sharma, Dung T. Le, Robert L. Ferris, Andrew D. Zelenetz, Ronald Levy, Izidore S. Lossos, Caron Jacobson, Radhakrishnan Ramchandren, John Godwin, A. Dimitrios Colevas, Roland Meier, Suba Krishnan, Xuemin Gu, Jaclyn Neely, John Timmerman, Claire I. Vanpouille-Box, Silvia C. Formenti, Sandra Demaria, Erik Wennerberg, Aranzazu Mediero, Bruce N. Cronstein, Michael P. Gustafson, AriCeli DiCostanzo, Courtney Wheatley, Chul-Ho Kim, Svetlana Bornschlegl, Dennis A. Gastineau, Bruce D. Johnson, Allan B. Dietz, Cameron MacDonald, Mark Bucsek, Guanxi Qiao, Bonnie Hylander, Elizabeth Repasky, William J. Turbitt, Yitong Xu, Andrea Mastro, Connie J. Rogers, Sita Withers, Ziming Wang, Lam T. Khuat, Cordelia Dunai, Bruce R. Blazar, Dan Longo, Robert Rebhun, Steven K. Grossenbacher, Arta Monjazeb, William J. Murphy, Scott Rowlinson, Giulia Agnello, Susan Alters, David Lowe, Nicole Scharping, Ashley V. Menk, Ryan Whetstone, Xue Zeng, Greg M. Delgoffe, Patricia M. Santos, Jian Shi, Greg Delgoffe, Misako Nagasaka, Ammar Sukari, Miranda Byrne-Steele, Wenjing Pan, Xiaohong Hou, Brittany Brown, Mary Eisenhower, Jian Han, Natalie Collins, Robert Manguso, Hans Pope, Yashaswi Shrestha, Jesse Boehm, W. Nicholas Haining, Kyle R. Cron, Ayelet Sivan, Keston Aquino-Michaels, Marco Orecchioni, Davide Bedognetti, Wouter Hendrickx, Claudia Fuoco, Filomena Spada, Francesco Sgarrella, Gianni Cesareni, Francesco Marincola, Kostas Kostarelos, Alberto Bianco, Lucia Delogu, Jessica Roelands, Sabri Boughorbel, Julie Decock, Scott Presnell, Ena Wang, Franco M. Marincola, Peter Kuppen, Michele Ceccarelli, Darawan Rinchai, Damien Chaussabel, Lance Miller, Andrew Nguyen, J. Zachary Sanborn, Charles Vaske, Shahrooz Rabizadeh, Kayvan Niazi, Steven Benz, Shashank Patel, Nicholas Restifo, James White, Sam Angiuoli, Mark Sausen, Sian Jones, Maria Sevdali, John Simmons, Victor Velculescu, Luis Diaz, Theresa Zhang, Jennifer S. Sims, Sunjay M. Barton, Angela Kadenhe-Chiweshe, Filemon Dela Cruz, Andrew T. Turk, Christopher F. Mazzeo, Andrew L. Kung, Jeffrey N. Bruce, Darrell J. Yamashiro, Eileen P. Connolly, Jason Baird, Marka Crittenden, David Friedman, Hong Xiao, Rom Leidner, Bryan Bell, Kristina Young, Michael Gough, Zhen Bian, Koby Kidder, Yuan Liu, Emily Curran, Xiufen Chen, Leticia P. Corrales, Justin Kline, Ethan G. Aguilar, Jennifer Guerriero, Alaba Sotayo, Holly Ponichtera, Alexandra Pourzia, Sara Schad, Ruben Carrasco, Suzan Lazo, Roderick Bronson, Anthony Letai, Richard S. Kornbluth, Sachin Gupta, James Termini, Elizabeth Guirado, Geoffrey W. Stone, Christina Meyer, Laura Helming, Nicholas Wilson, Robert Hofmeister, Natalie J. Neubert, Laure Tillé, David Barras, Charlotte Soneson, Petra Baumgaertner, Donata Rimoldi, David Gfeller, Mauro Delorenzi, Silvia A. Fuertes Marraco, Daniel E. Speiser, Tara S. Abraham, Bo Xiang, Michael S. Magee, Scott A. Waldman, Adam E. Snook, Wojciech Blogowski, Ewa Zuba-Surma, Marta Budkowska, Daria Salata, Barbara Dolegowska, Teresa Starzynska, Leo Chan, Srinivas Somanchi, Kelsey McCulley, Dean Lee, Nico Buettner, Feng Shi, Paisley T. Myers, Stuart Curbishley, Sarah A. Penny, Lora Steadman, David Millar, Ellen Speers, Nicola Ruth, Gabriel Wong, Robert Thimme, David Adams, Mark Cobbold, Remy Thomas, Mariam Al-Muftah, Michael KK Wong, Michael Morse, Joseph I. Clark, Howard L. Kaufman, Gregory A. Daniels, Hong Hua, Tharak Rao, Janice P. Dutcher, Kai Kang, Yogen Saunthararajah, Vamsidhar Velcheti, Vikas Kumar, Firoz Anwar, Amita Verma, Zinal Chheda, Gary Kohanbash, John Sidney, Kaori Okada, Shruti Shrivastav, Diego A. Carrera, Shuming Liu, Naznin Jahan, Sabine Mueller, Ian F. Pollack, Angel M. Carcaboso, Alessandro Sette, Yafei Hou, Hideho Okada, Jessica J. Field, Weiping Zeng, Vincent FS Shih, Che-Leung Law, Peter D. Senter, Shyra J. Gardai, Nicole M. Okeley, Jennifer G. Abelin, Abu Z. Saeed, Stacy A. Malaker, Jeffrey Shabanowitz, Stephen T. Ward, Donald F. Hunt, Pam Profusek, Laura Wood, Dale Shepard, Petros Grivas, Kerstin Kapp, Barbara Volz, Detlef Oswald, Burghardt Wittig, Manuel Schmidt, Julian P. Sefrin, Lars Hillringhaus, Valeria Lifke, Alexander Lifke, Anna Skaletskaya, Jose Ponte, Thomas Chittenden, Yulius Setiady, Eva Sivado, Vincent Thomas, Meddy El Alaoui, Sébastien Papot, Charles Dumontet, Mike Dyson, John McCafferty, Said El Alaoui, Praveen K. Bommareddy, Andrew Zloza, Frederick Kohlhapp, Ann W. Silk, Sachin Jhawar, Tomas Paneque, Jenna Newman, Pedro Beltran, Felicia Cao, Bang-Xing Hong, Tania Rodriguez-Cruz, Xiao-Tong Song, Stephen Gottschalk, Hugo Calderon, Sam Illingworth, Alice Brown, Kerry Fisher, Len Seymour, Brian Champion, Emma Eriksson, Jessica Wenthe, Ann-Charlotte Hellström, Gabriella Paul-Wetterberg, Angelica Loskog, Ioanna Milenova, Magnus Ståhle, Justyna Jarblad-Leja, Gustav Ullenhag, Anna Dimberg, Rafael Moreno, Ramon Alemany, Sharad Goyal, Ann Silk, Janice Mehnert, Nashat Gabrail, Jennifer Bryan, Daniel Medina, Leah Mitchell, Kader Yagiz, Fernando Lopez, Daniel Mendoza, Anthony Munday, Harry Gruber, Douglas Jolly, Steven Fuhrmann, Sasa Radoja, Wei Tan, Aldo Pourchet, Alan Frey, Ian Mohr, Matthew Mulvey, Robert H. I. Andtbacka, Merrick Ross, Sanjiv Agarwala, Kenneth Grossmann, Matthew Taylor, John Vetto, Rogerio Neves, Adil Daud, Hung Khong, Stephanie M. Meek, Richard Ungerleider, Scott Welden, Maki Tanaka, Matthew Williams, Sigrun Hallmeyer, Bernard Fox, Zipei Feng, Christopher Paustian, Carlo Bifulco, Sadia Zafar, Otto Hemminki, Simona Bramante, Lotta Vassilev, Hongjie Wang, Andre Lieber, Silvio Hemmi, Tanja de Gruijl, Anna Kanerva, Tameem Ansari, Srividya Sundararaman, Diana Roen, Paul Lehmann, Anja C. Bloom, Lewis H. Bender, Ian B. Walters, Jay A. Berzofsky, Fanny Chapelin, Eric T. Ahrens, Jeff DeFalco, Michael Harbell, Amy Manning-Bog, Alexander Scholz, Danhui Zhang, Gilson Baia, Yann Chong Tan, Jeremy Sokolove, Dongkyoon Kim, Kevin Williamson, Xiaomu Chen, Jillian Colrain, Gregg Espiritu Santo, Ngan Nguyen, Wayne Volkmuth, Norman Greenberg, William Robinson, Daniel Emerling, Charles G. Drake, Daniel P. Petrylak, Emmanuel S. Antonarakis, Adam S. Kibel, Nancy N. Chang, Tuyen Vu, Dwayne Campogan, Heather Haynes, James B. Trager, Nadeem A. Sheikh, David I. Quinn, Peter Kirk, Murali Addepalli, Thomas Chang, Ping Zhang, Marina Konakova, Katsunobu Hagihara, Steven Pai, Laurie VanderVeen, Palakshi Obalapur, Peiwen Kuo, Phi Quach, Lawrence Fong, Deborah H. Charych, Jonathan Zalevsky, John L. Langowski, Yolanda Kirksey, Ravi Nutakki, Shalini Kolarkar, Rhoneil Pena, Ute Hoch, Stephen K. Doberstein, John Cha, Zach Mallon, Myra Perez, Amanda McDaniel, Snjezana Anand, Darrin Uecker, Richard Nuccitelli, Eva Wieckowski, Ravikumar Muthuswamy, Roshni Ravindranathan, Ariana N. Renrick, Menaka Thounaojam, Portia Thomas, Samuel Pellom, Anil Shanker, Duafalia Dudimah, Alan Brooks, Yu-Lin Su, Tomasz Adamus, Qifang Zhang, Sergey Nechaev, Marcin Kortylewski, Spencer Wei, Clark Anderson, Chad Tang, Jonathan Schoenhals, Efrosini Tsouko, John Heymach, Patricia de Groot, Joe Chang, Kenneth R. Hess, Adi Diab, Padmanee Sharma, David Hong, James Welsh, Andrea J. Parsons, Jardin Leleux, Stephane Ascarateil, Marie Eve Koziol, Dina Bai, Peihong Dai, Weiyi Wang, Ning Yang, Stewart Shuman, Liang Deng, Patrick Dillon, Gina Petroni, David Brenin, Kim Bullock, Walter Olson, Mark E. Smolkin, Kelly Smith, Carmel Nail, Craig L. Slingluff, Meenu Sharma, Faisal Fa’ak, Louise Janssen, Hiep Khong, Zhilan Xiao, Yared Hailemichael, Manisha Singh, Christina Vianden, Willem W. Overwijk, Andrea Facciabene, Pierini Stefano, Fang Chongyung, Stavros Rafail, Michael Nielsen, Peter Vanderslice, Darren G. Woodside, Robert V. Market, Ronald J. Biediger, Upendra K. Marathi, Kevin Hollevoet, Nick Geukens, Paul Declerck, Nathalie Joly, Laura McIntosh, Eustache Paramithiotis, Magnus Rizell, Malin Sternby, Bengt Andersson, Alex Karlsson-Parra, Rui Kuai, Lukasz Ochyl, Anna Schwendeman, James Moon, Weiwen Deng, Thomas E. Hudson, Bill Hanson, Chris S. Rae, Joel Burrill, Justin Skoble, George Katibah, Michele deVries, Peter Lauer, Thomas W. Dubensky, Xin Chen, Li Zhou, Xiubao Ren, Charu Aggarwal, Drishty Mangrolia, Roger Cohen, Gregory Weinstein, Matthew Morrow, Joshua Bauml, Kim Kraynyak, Jean Boyer, Jian Yan, Jessica Lee, Laurent Humeau, Sandra Oyola, Susan Duff, David Weiner, Zane Yang, Mark Bagarazzi, Douglas G. McNeel, Jens Eickhoff, Robert Jeraj, Mary Jane Staab, Jane Straus, Brian Rekoske, Glenn Liu, Marit Melssen, William Grosh, Nikole Varhegyi, Nadejda Galeassi, Donna H. Deacon, Elizabeth Gaughan, Maurizio Ghisoli, Minal Barve, Robert Mennel, Gladice Wallraven, Luisa Manning, Neil Senzer, John Nemunaitis, Masahiro Ogasawara, Shuichi Ota, Kaitlin M. Peace, Diane F. Hale, Timothy J. Vreeland, Doreen O. Jackson, John S. Berry, Alfred F. Trappey, Garth S. Herbert, Guy T. Clifton, Mark O. Hardin, Anne Toms, Na Qiao, Jennifer Litton, George E. Peoples, Elizabeth A. Mittendorf, Lila Ghamsari, Emilio Flano, Judy Jacques, Biao Liu, Jonathan Havel, Vladimir Makarov, Timothy A. Chan, Jessica B. Flechtner, John Facciponte, Stefano Ugel, Francesco De Sanctis, George Coukos, Sébastien Paris, Agnes Pottier, Laurent Levy, Bo Lu, Federica Cappuccini, Emily Pollock, Richard Bryant, Freddie Hamdy, Adrian Hill, Irina Redchenko, Hussein Sultan, Takumi Kumai, Valentyna Fesenkova, Esteban Celis, Ingrid Fernando, Claudia Palena, Justin M. David, Elizabeth Gabitzsch, Frank Jones, James L. Gulley, Mireia Uribe Herranz, Hiroshi Wada, Atsushi Shimizu, Toshihiro Osada, Satoshi Fukaya, Eiji Sasaki, Milad Abolhalaj, David Askmyr, Kristina Lundberg, Ann-Sofie Albrekt, Lennart Greiff, Malin Lindstedt, Dallas B. Flies, Tomoe Higuchi, Wojciech Ornatowski, Jaryse Harris, Sarah F. Adams, Todd Aguilera, Marjan Rafat, Laura Castellini, Hussein Shehade, Mihalis Kariolis, Dadi Jang, Rie vonEbyen, Edward Graves, Lesley Ellies, Erinn Rankin, Albert Koong, Amato Giaccia, Reham Ajina, Shangzi Wang, Jill Smith, Mariaelena Pierobon, Sandra Jablonski, Emanuel Petricoin, Louis M. Weiner, Lorcan Sherry, John Waller, Mark Anderson, Alison Bigley, Chantale Bernatchez, Cara Haymaker, Harriet Kluger, Michael Tetzlaff, Natalie Jackson, Ivan Gergel, Mary Tagliaferri, Patrick Hwu, Mario Snzol, Michael Hurwitz, Theresa Barberi, Allison Martin, Rahul Suresh, David Barakat, Sarah Harris-Bookman, Charles Drake, Alan Friedman, Sara Berkey, Stephanie Downs-Canner, Robert P. Edwards, Tyler Curiel, Kunle Odunsi, Tullia C. Bruno, Brandon Moore, Olivia Squalls, Peggy Ebner, Katherine Waugh, John Mitchell, Wilbur Franklin, Daniel Merrick, Martin McCarter, Brent Palmer, Jeffrey Kern, Dario Vignali, Jill Slansky, Anissa S. H. Chan, Xiaohong Qiu, Kathryn Fraser, Adria Jonas, Nadine Ottoson, Keith Gordon, Takashi O. Kangas, Steven Leonardo, Kathleen Ertelt, Richard Walsh, Mark Uhlik, Jeremy Graff, Nandita Bose, Ravi Gupta, Nitin Mandloi, Kiran Paul, Ashwini Patil, Rekha Sathian, Aparna Mohan, Malini Manoharan, Amitabha Chaudhuri, Yu Chen, Jing Lin, Yun-bin Ye, Chun-wei Xu, Gang Chen, Zeng-qing Guo, Andrey Komarov, Alex Chenchik, Michael Makhanov, Costa Frangou, Yi Zheng, Carla Coltharp, Darryn Unfricht, Ryan Dilworth, Leticia Fridman, Linying Liu, Milind Rajopadhye, Peter Miller, Fernando Concha-Benavente, Julie Bauman, Sumita Trivedi, Raghvendra Srivastava, James Ohr, Dwight Heron, Uma Duvvuri, Seungwon Kim, Heather Torrey, Toshi Mera, Yoshiaki Okubo, Eva Vanamee, Rosemary Foster, Denise Faustman, Edward Stack, Daisuke Izaki, Kristen Beck, Dan Tong Jia, Paul Armenta, Ashley White-Stern, Douglas Marks, Bret Taback, Basil Horst, Laura Hix Glickman, David B. Kanne, Kelsey S. Gauthier, Anthony L. Desbien, Brian Francica, Justin L. Leong, Leonard Sung, Ken Metchette, Shailaja Kasibhatla, Anne Marie Pferdekamper, Lianxing Zheng, Charles Cho, Yan Feng, Jeffery M. McKenna, John Tallarico, Steven Bender, Chudi Ndubaku, Sarah M. McWhirter, Elena Gonzalez Gugel, Charles J. M. Bell, Adiel Munk, Luciana Muniz, Nina Bhardwaj, Fei Zhao, Kathy Evans, Christine Xiao, Alisha Holtzhausen, Brent A. Hanks, Nathalie Scholler, Catherine Yin, Pien Van der Meijs, Andrew M. Prantner, Cecile M. Krejsa, Leia Smith, Brian Johnson, Daniel Branstetter, Paul L. Stein, Juan C. Jaen, Joanne BL Tan, Ada Chen, Timothy Park, Jay P. Powers, Holly Sexton, Guifen Xu, Steve W. Young, Ulrike Schindler, Wentao Deng, David John Klinke, Hannah M. Komar, Gregory Serpa, Omar Elnaggar, Philip Hart, Carl Schmidt, Mary Dillhoff, Ming Jin, Michael C. Ostrowski, Madhuri Koti, Katrina Au, Nichole Peterson, Peter Truesdell, Gillian Reid-Schachter, Charles Graham, Andrew Craig, Julie-Ann Francis, Beatrix Kotlan, Timea Balatoni, Emil Farkas, Laszlo Toth, Mihaly Ujhelyi, Akos Savolt, Zoltan Doleschall, Szabolcs Horvath, Klara Eles, Judit Olasz, Orsolya Csuka, Miklos Kasler, Gabriella Liszkay, Eytan Barnea, Collin Blakely, Patrick Flynn, Reid Goodman, Raphael Bueno, David Sugarbaker, David Jablons, V. Courtney Broaddus, Brian West, Paul R. Kunk, Joseph M. Obeid, Kevin Winters, Patcharin Pramoonjago, Edward B. Stelow, Todd W. Bauer, Osama E. Rahma, Adam Lamble, Yoko Kosaka, Fei Huang, Kate A. Saser, Homer Adams, Christina E. Tognon, Ted Laderas, Shannon McWeeney, Marc Loriaux, Jeffery W. Tyner, Brian J. Druker, Evan F. Lind, Zhuqing Liu, Shanhong Lu, Lawrence P. Kane, Gulidanna Shayan, Julia Femel, Ryan Lane, Jamie Booth, Amanda W. Lund, Anthony Rodriguez, Victor H. Engelhard, Alessandra Metelli, Bill X. Wu, Caroline W. Fugle, Rachidi Saleh, Shaoli Sun, Jennifer Wu, Bei Liu, Zihai Li, Zachary S. Morris, Emily I. Guy, Clinton Heinze, Jasdeep Kler, Monica M. Gressett, Lauryn R. Werner, Stephen D. Gillies, Alan J. Korman, Hans Loibner, Jacquelyn A. Hank, Alexander L. Rakhmilevich, Paul M. Harari, Paul M. Sondel, Erica Huelsmann, Joseph Broucek, Dorothee Brech, Tobias Straub, Martin Irmler, Johannes Beckers, Florian Buettner, Elke Schaeffeler, Matthias Schwab, Elfriede Noessner, Alison Wolfreys, Andre Da Costa, John Silva, Andrea Crosby, Ludovicus Staelens, Graham Craggs, Annick Cauvin, Sean Mason, Alison M. Paterson, Andrew C. Lake, Caroline M. Armet, Rachel W. O’Connor, Jonathan A. Hill, Emmanuel Normant, Ammar Adam, Detlev M. Biniszkiewicz, Scott C. Chappel, Vito J. Palombella, Pamela M. Holland, Annette Becker, Manmohan R. Leleti, Eric Newcomb, Joanne B. L. Tan, Suthee Rapisuwon, Arash Radfar, Kellie Gardner, Geoffrey Gibney, Michael Atkins, Keith R. Rennier, Robert Crowder, Ping Wang, Russell K. Pachynski, Rosa M. Santana Carrero, Sarai Rivas, Figen Beceren-Braun, Scott Anthony, Kimberly S. Schluns, Deepali Sawant, Maria Chikina, Hiroshi Yano, Creg Workman, Elise Salerno, Ileana Mauldin, Donna Deacon, Sofia Shea, Joel Pinczewski, Thomas Gajewski, Stefani Spranger, Brendan Horton, Akiko Suzuki, Pamela Leland, Bharat H. Joshi, Raj K. Puri, Randy F. Sweis, Riyue Bao, Jason Luke, Marie-Nicole Theodoraki, Frances-Mary Mogundo, Haejung Won, Dayson Moreira, Chan Gao, Xingli Zhao, Priyanka Duttagupta, Jeremy Jones, Massimo D’Apuzzo, and Sumanta Pal
- Subjects
0301 basic medicine ,Pharmacology ,Cancer Research ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Immunology ,Cancer ,Immunotherapy ,medicine.disease ,3. Good health ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Oncology ,030220 oncology & carcinogenesis ,Family medicine ,Molecular Medicine ,Immunology and Allergy ,Medicine ,business - Abstract
O1 IL-15 primes an mTOR-regulated gene-expression program to prolong anti-tumor capacity of human natural killer cells #### Andreas Lundqvist1, Vincent van Hoef1, Xiaonan Zhang1, Erik Wennerberg2, Julie Lorent1, Kristina Witt1, Laia Masvidal Sanz1, Shuo Liang1, Shannon Murray3, Ola Larsson1
- Published
- 2016
- Full Text
- View/download PDF
11. Application of DBS sampling in combination with LC–MS/MS for pharmacokinetic evaluation of a compound with species-specific blood-to-plasma partitioning
- Author
-
Craig Uyeda, Marcus Soto, Jiyun S Chen, Timothy J. Carlson, Guifen Xu, Mary C. Wells, Tom Huang, Christopher A. James, Ruta Phadnis, and Brian Stouch
- Subjects
Male ,Bioanalysis ,Clinical Biochemistry ,Pharmacology ,Analytical Chemistry ,Rats, Sprague-Dawley ,Plasma ,Dogs ,Species Specificity ,Pharmacokinetics ,Tandem Mass Spectrometry ,In vivo ,Lc ms ms ,Animals ,General Pharmacology, Toxicology and Pharmaceutics ,Chromatography, High Pressure Liquid ,Blood Specimen Collection ,Chromatography ,Chemistry ,Reproducibility of Results ,Blood Proteins ,General Medicine ,Rats ,Dried blood spot ,Medical Laboratory Technology ,Pharmaceutical Preparations ,Injections, Intravenous ,Dried Blood Spot Testing ,Quantitative analysis (chemistry) ,Protein Binding - Abstract
Background: Dried blood spot (DBS) sampling in combination with LC–MS/MS has been used increasingly in drug discovery for quantitative analysis to support pharmacokinetic (PK) studies. In this study, we assessed the effect of blood-to-plasma (B:P) partitioning on the bioanalytical performance and PK data acquired by DBS for a compound AMG-1 with species and concentration-dependent B:P ratio. Results: B:P partitioning did not adversely affect bioanalytical performance of DBS for AMG-1. For rat, (B:P ratio of 0.63), PK profiles from DBS and plasma methods were comparable. For dog, concentration-dependence of B:P ratio was observed both in vivo and in vitro. Additional studies demonstrated concentration-dependence of the compound’s unbound fraction in plasma, which may contribute to the concentration-dependence of the B:P ratio. Conclusion: DBS is a promising sampling technique for preclinical pharmacokinetic studies. For compounds with high B:P ratio, caution needs to be applied for data comparison and interpretation between matrices.
- Published
- 2012
- Full Text
- View/download PDF
12. Discovery of amide replacements that improve activity and metabolic stability of a bis-amide smoothened antagonist hit
- Author
-
Minqing Rong, Brian Lucas, Wendy Zhong, Guifen Xu, Gary Lee, Ben Jiang, Angela Chong, Qiuping Ye, Michael DeGraffenreid, Tom Huang, Dineli Wickramasinghe, Randall W. Hungate, Wade Aaron, Michael G. Johnson, Jessica Orf, Dustin McMinn, Matthew L. Brown, Richard J. Austin, Maria M. Toteva, Jacob Kaizerman, and Jay P. Powers
- Subjects
Molecular Structure ,Drug discovery ,Chemistry ,Organic Chemistry ,Clinical Biochemistry ,Antagonist ,Pharmaceutical Science ,Stereoisomerism ,Amides ,Biochemistry ,Hedgehog signaling pathway ,In vitro ,High-Throughput Screening Assays ,Structure-Activity Relationship ,chemistry.chemical_compound ,In vivo ,Amide ,Drug Discovery ,Molecular Medicine ,Structure–activity relationship ,Enzyme Inhibitors ,Smoothened ,Molecular Biology ,Acyltransferases - Abstract
A bis-amide antagonist of Smoothened, a seven-transmembrane receptor in the Hedgehog signaling pathway, was discovered via high throughput screening. In vitro and in vivo experiments demonstrated that the bis-amide was susceptible to N-acyl transferase mediated amide scission. Several bioisosteric replacements of the labile amide that maintained in vitro potency were identified and shown to be metabolically stable in vitro and in vivo.
- Published
- 2011
- Full Text
- View/download PDF
13. Discovery and molecular basis of potent noncovalent inhibitors of fatty acid amide hydrolase (FAAH)
- Author
-
Xiaoshan Min, Stephen T. Thibault, Craig Uyeda, Zhulun Wang, Timothy J. Carlson, Zhihua Ma, Guifen Xu, Darin J. Gustin, Michelle Lindstrom, Frank Kayser, Yihong Li, Nigel Walker, Haoda Xu, and Amy Porter
- Subjects
Models, Molecular ,Oleamide ,Stereochemistry ,Amidohydrolases ,chemistry.chemical_compound ,Coumarins ,Tandem Mass Spectrometry ,Fatty acid amide hydrolase ,Drug Discovery ,Hydrolase ,Catalytic triad ,Escherichia coli ,medicine ,Animals ,Humans ,Urea ,Enzyme Inhibitors ,Multidisciplinary ,Molecular Structure ,biology ,Drug discovery ,Active site ,Anandamide ,Biological Sciences ,Rats ,nervous system ,Mechanism of action ,chemistry ,Biochemistry ,biology.protein ,Benzimidazoles ,Spectrophotometry, Ultraviolet ,lipids (amino acids, peptides, and proteins) ,medicine.symptom ,Crystallization ,psychological phenomena and processes - Abstract
Fatty acid amide hydrolase (FAAH), an amidase-signature family member, is an integral membrane enzyme that degrades lipid amides including the endogenous cannabinoid anandamide and the sleep-inducing molecule oleamide. Both genetic knock out and pharmacological administration of FAAH inhibitors in rodent models result in analgesic, anxiolytic, and antiinflammatory phenotypes. Targeting FAAH activity, therefore, presents a promising new therapeutic strategy for the treatment of pain and other neurological-related or inflammatory disorders. Nearly all FAAH inhibitors known to date attain their binding potency through a reversible or irreversible covalent modification of the nucleophile Ser241 in the unusual Ser-Ser-Lys catalytic triad. Here, we report the discovery and mechanism of action of a series of ketobenzimidazoles as unique and potent noncovalent FAAH inhibitors. Compound 2 , a representative of these ketobenzimidazoles, was designed from a series of ureas that were identified from high-throughput screening. While urea compound 1 is characterized as an irreversible covalent inhibitor, the cocrystal structure of FAAH complexed with compound 2 reveals that these ketobenzimidazoles, though containing a carbonyl moiety, do not covalently modify Ser241. These inhibitors achieve potent inhibition of FAAH activity primarily from shape complementarity to the active site and through numerous hydrophobic interactions. These noncovalent compounds exhibit excellent selectivity and good pharmacokinetic properties. The discovery of this distinctive class of inhibitors opens a new avenue for modulating FAAH activity through nonmechanism-based inhibition.
- Published
- 2011
- Full Text
- View/download PDF
14. Identification of potent, noncovalent fatty acid amide hydrolase (FAAH) inhibitors
- Author
-
Michelle Lindstrom, Timothy J. Carlson, Guifen Xu, Xiaoshan Min, Zhihua Ma, Frank Kayser, Shou-Hua Xiao, Dianna Lester-Zeiner, Christine Hedberg, Richard V. Connors, Zhulun Wang, Cesar Meleza, Yihong Li, Cris Guimaraes, Darin J. Gustin, and Amy Porter
- Subjects
Lactams ,Molecular model ,Stereochemistry ,Clinical Biochemistry ,Pharmaceutical Science ,Crystallography, X-Ray ,Biochemistry ,Chemical synthesis ,Amidohydrolases ,Amidase ,Structure-Activity Relationship ,Fatty acid amide hydrolase ,Drug Discovery ,medicine ,Animals ,Humans ,Urea ,Structure–activity relationship ,Computer Simulation ,Spiro Compounds ,Enzyme Inhibitors ,Molecular Biology ,chemistry.chemical_classification ,Binding Sites ,biology ,Chemistry ,Organic Chemistry ,Rats ,Enzyme ,nervous system ,Mechanism of action ,Enzyme inhibitor ,biology.protein ,Molecular Medicine ,lipids (amino acids, peptides, and proteins) ,medicine.symptom ,psychological phenomena and processes - Abstract
Starting from a series of ureas that were determined to be mechanism-based inhibitors of FAAH, several spirocyclic ureas and lactams were designed and synthesized. These efforts identified a series of novel, noncovalent FAAH inhibitors with in vitro potency comparable to known covalent FAAH inhibitors. The mechanism of action for these compounds was determined through a combination of SAR and co-crystallography with rat FAAH.
- Published
- 2011
- Full Text
- View/download PDF
15. Addressing PXR liabilities of phthalazine-based hedgehog/smoothened antagonists using novel pyridopyridazines
- Author
-
Ben Jiang, Michael G. Johnson, Maria M. Toteva, Dustin McMinn, Brian Lucas, Richard J. Austin, Wendy Zhong, Qiuping Ye, Matthew L. Brown, Tom Huang, Guifen Xu, Randall W. Hungate, Dineli Wickramasinghe, Jessica Orf, Gary Lee, Minqing Rong, Songzhu An, Wade Aaron, Angela Chong, and Jacob Kaizerman
- Subjects
Receptors, Steroid ,Clinical Biochemistry ,Pharmaceutical Science ,Biochemistry ,Piperazines ,Receptors, G-Protein-Coupled ,Mice ,Structure-Activity Relationship ,chemistry.chemical_compound ,Drug Discovery ,Animals ,Humans ,Structure–activity relationship ,Hedgehog Proteins ,Molecular Biology ,Hedgehog ,Pregnane X receptor ,Organic Chemistry ,Pregnane X Receptor ,Smoothened Receptor ,Hedgehog signaling pathway ,Rats ,Pyridazines ,chemistry ,Microsomes, Liver ,Cancer research ,Phthalazines ,Molecular Medicine ,Tylosin ,Signal transduction ,Phthalazine ,Smoothened ,Signal Transduction - Abstract
Pyridopyridazine antagonists of the hedgehog signaling pathway are described. Designed to optimize our previously described phthalazine smoothened antagonists, a representative compound eliminates a PXR liability while retaining potency and in vitro metabolic stability. Moreover, the compound has improved efficacy in a hedgehog/smoothened signaling mouse pharmacodynamic model.
- Published
- 2010
- Full Text
- View/download PDF
16. Investigation of collision-induced dissociations involving odd-electron ion formation under positive electrospray ionization conditions using accurate mass
- Author
-
Shichang Miao, Jennifer Zhang, Guifen Xu, Jennifer K. Huang, Tom Huang, and Timothy J. Carlson
- Subjects
Chemical ionization ,Collision-induced dissociation ,Chemistry ,Electrospray ionization ,Organic Chemistry ,Analytical chemistry ,Atmospheric-pressure chemical ionization ,Mass spectrometry ,Analytical Chemistry ,Ion ,Fragmentation (mass spectrometry) ,Computational chemistry ,Quadrupole ion trap ,Spectroscopy - Abstract
Collision induced dissociation (CID) has been extensively used for structure elucidation. CID in the electrospray ionization (ESI) and atmospheric pressure chemical ionization (APCI) modes has been found to generate mostly even-electron fragment ions while it has been occasionally reported to form odd-electron free radical ions. However, the structural requirements and the fragmentation mechanisms for free-radical CIDs have not been well characterized in the literature. For this purpose, we studied a series of aromatic and non-aromatic compounds such as sulfonamides, N-aryl amides, tert-butyl-substituted aromatic compounds, aryl alkyl ethers, and O-alkyl aryl oximes using the LTQ™ and LTQ Orbitrap™ linear ion trap mass spectrometers. The accurate measurement of the fragment ion masses established the unambiguous assignment of the fragment structures resulting from the test compounds. Our results showed that free radical fragmentation is structure dependent and is to a large extent correlated with the neighboring groups in the structures that stabilize the newly formed free radical ions. Copyright © 2010 John Wiley & Sons, Ltd.
- Published
- 2010
- Full Text
- View/download PDF
17. Identification and Characterization of a Non-retinoid Ligand for Retinol-binding Protein 4 Which Lowers Serum Retinol-binding Protein 4 Levels in Vivo
- Author
-
Richard V. Connors, Steve Thibault, Zhulun Wang, Pingchen Fan, Alykhan Motani, Haoda Xu, Nigel Walker, Ying Zhang, Qingxiang Liu, Hoa Le, Guifen Xu, Karen Siegler, Bei Shan, Sheree Johnstone, Yingcai Wang, Peter Coward, and Marion Conn
- Subjects
medicine.medical_specialty ,medicine.drug_class ,medicine.medical_treatment ,Crystallography, X-Ray ,Ligands ,Biochemistry ,Mice ,chemistry.chemical_compound ,Insulin resistance ,Piperidines ,Internal medicine ,Diabetes Mellitus ,medicine ,Animals ,Humans ,Insulin ,Retinoid ,Vitamin A ,Molecular Biology ,Mice, Knockout ,Retinol binding protein 4 ,biology ,Binding protein ,Retinol ,Cell Biology ,medicine.disease ,Dietary Fats ,Protein Structure, Tertiary ,Metabolism and Bioenergetics ,Transthyretin ,Retinol binding protein ,Endocrinology ,chemistry ,biology.protein ,Insulin Resistance ,Heterocyclic Compounds, 3-Ring ,Retinol-Binding Proteins, Plasma - Abstract
Retinol-binding protein 4 (RBP4) transports retinol from the liver to extrahepatic tissues, and RBP4 lowering is reported to improve insulin sensitivity in mice. We have identified A1120, a high affinity (Ki = 8.3 nm) non-retinoid ligand for RBP4, which disrupts the interaction between RBP4 and its binding partner transthyretin. Analysis of the RBP4-A1120 co-crystal structure reveals that A1120 induces critical conformational changes at the RBP4-transthyretin interface. Administration of A1120 to mice lowers serum RBP4 and retinol levels but, unexpectedly, does not improve insulin sensitivity. In addition, we show that Rpb4-/- mice display normal insulin sensitivity and are not protected from high fat diet-induced insulin resistance. We conclude that lowering RBP4 levels does not improve insulin sensitivity in mice. Therefore, RBP4 lowering may not be an effective strategy for treating diabetes.
- Published
- 2009
- Full Text
- View/download PDF
18. Disposition and Metabolic Profiles of [ 14 C]Viramidine and [ 14 C]Ribavirin in Rat and Monkey Red Blood Cells and Liver
- Author
-
Li-Tain Yeh, David Lourenco, Guifen Xu, and Chin-Chung Lin
- Subjects
Male ,Drug ,medicine.medical_specialty ,Erythrocytes ,viruses ,media_common.quotation_subject ,Biology ,Antiviral Agents ,Chromatography, DEAE-Cellulose ,Rats sprague dawley ,Rats, Sprague-Dawley ,chemistry.chemical_compound ,Pharmacokinetics ,Oral administration ,Internal medicine ,Ribavirin ,Area under curve ,medicine ,Animals ,Pharmacology (medical) ,Biotransformation ,media_common ,Pharmacology ,virus diseases ,Disposition ,biochemical phenomena, metabolism, and nutrition ,digestive system diseases ,Rats ,Macaca fascicularis ,Red blood cell ,Infectious Diseases ,medicine.anatomical_structure ,Endocrinology ,Liver ,chemistry ,Area Under Curve - Abstract
The disposition and metabolic profiles of [ 14 C]viramidine and [ 14 C]ribavirin were compared in rat and monkey red blood cells and liver. Our data reveal that the total ribavirin-related components (ribavirin plus its mono-, di-, and triphosphate metabolites) may account for most of the drug in monkey liver following prolonged oral administration of viramidine.
- Published
- 2004
- Full Text
- View/download PDF
19. Ultra sensitive method for the determination of 9-(2-phosphonylmethoxyethyl)adenine in human serum by liquid chromatography–tandem mass spectrometry
- Author
-
Liset Garcia, Guifen Xu, Chin-Chung Lin, Li-Tain Yeh, Yifei Liu, and Christine Xu
- Subjects
Electrospray ,Chromatography ,Chemistry ,Adenine ,Electrospray ionization ,Clinical Biochemistry ,Organophosphonates ,Reproducibility of Results ,Cell Biology ,General Medicine ,Prodrug ,Tandem mass spectrometry ,Antiviral Agents ,Sensitivity and Specificity ,Biochemistry ,High-performance liquid chromatography ,Mass Spectrometry ,Analytical Chemistry ,Liquid chromatography–mass spectrometry ,Humans ,Solid phase extraction ,Quantitative analysis (chemistry) ,Chromatography, Liquid - Abstract
An ultra sensitive method for the direct measurement of 9-(2-phosphonylmethoxyethyl)adenine (PMEA), an antiviral agent for hepatitis B, in human serum using high performance liquid chromatography/tandem mass spectrometry (LC–MS/MS) has been developed. This method involves the addition of [13C]PMEA (contains 5 13C) as internal standard, the purification and enrichment by a MCX solid phase extraction (SPE) cartridge, and quantitative analysis using LC–MS/MS. The MS/MS is selected to monitor the m/z 272→134 and m/z 277→m/z 139 transitions for PMEA and [13C]PMEA, respectively, using negative electrospray ionization. The MS/MS response is linear over a concentration of 0.1–10 ng/ml with a lower limit of quantitation (LLOQ) of 0.1 ng/ml. The mean inter-assay accuracy (%Bias) for quality control (QC) at 0.1, 0.25, 1.0, and 10 ng/ml are 10, 1.6, −0.8, and 0.0%, respectively. The mean inter-assay precision (%CV) for the corresponding QCs is 3.9, 3.8, 5.3, and 3.4%, respectively. The method has been used to determine PMEA concentration in human serum following a single oral administration of a PMEA pro-drug at dose of 10 and 30 mg.
- Published
- 2004
- Full Text
- View/download PDF
20. The characteristics of Triassic detrital components and provenance analysis in the western Tabei Uplift
- Author
-
Jun Jiang, Xiaoni Wang, Yanqiang Chi, Guifen Xu, and Jingyan Liu
- Subjects
Provenance ,Source rock ,Heavy mineral ,Clastic rock ,Metamorphic rock ,Geochemistry ,Sedimentary rock ,Petrology ,Geology ,Conglomerate - Abstract
KEYWORD: detrital component characteristics; provenance analysis; Triassic. ABSTRACT: Triassic in the western Tabei uplift is detrital sedimentary. Based on the data of the conglomerate, sandstone framework components and heavy mineral to analyze the Triassic of research area, the result shows that the source rocks are metamorphic rocks, magmatic rocks and sedimentary rocks, whose sources come from Xiqiu Uplift and Luntai Uplift. The western of research area is magmatic and sedimentary rock deposit zone, where is mainly influenced by the Xiqiu Uplift. The middle part of research area is metamorphic and sedimentary rock deposit zone where is mainly influenced by the Xiqiu Uplift and Luntai Uplift. The eastern of research area is metamorphic, sedimentary and magmatic rock deposit zone where is mainly influenced by the Luntai Uplift. The proximal clastic deposits are mainly influenced by the hydrodynamic conditions, palaeohigh and tectonization, so provenance has the characteristics of region and multiple
- Published
- 2015
- Full Text
- View/download PDF
21. Study on the Sequence division and correlation of the Kapushaliang Group in the Western Tabei Uplift
- Author
-
Guifen Xu, Yongfu Liu, and Yungang Ji
- Subjects
Sequence (geology) ,Paleontology ,Stage (stratigraphy) ,Group (stratigraphy) ,Seismic stratigraphy ,Drilling ,Sedimentary rock ,Sequence stratigraphy ,Division (mathematics) ,Geology - Abstract
Based on the theory of sequence stratigraphy and seismic stratigraphy, with the integral analysis of the seismic, drilling and logging data, the sequence stratigraphy framework of Kapushaliang Group in the western Tabei Uplift is established. A 2nd-order sequence surface and three 3rd-order sequences surfaces was recognized.The Kapushaliang Group was divided into four 3rd-order sequences. The 3rd-order sequence was controlled by palaeogeomorphology.The bottom sequence overlaped from the sag to the Uplift. At the stage of SQ4, the northern and southern sides of the Uplift were linked together. The sedimentary center migrated in different sequence stages.
- Published
- 2015
- Full Text
- View/download PDF
22. FLT3 and CDK4/6 inhibitors: signaling mechanisms and tumor burden in subcutaneous and orthotopic mouse models of acute myeloid leukemia
- Author
-
Yaping Zhang, Ji Ma, Yilong Zhang, Margaret F. Weidner, Guifen Xu, Justin N. Huard, Yu-Nien Sun, Mita Kuchimanchi, Yang Xu, Cheng-Pang Hsu, Jian-Feng Lu, and David Z. D'Argenio
- Subjects
Niacinamide ,Cell signaling ,Myeloid ,Population ,Biology ,Pharmacology ,Article ,chemistry.chemical_compound ,Mice ,Cell Line, Tumor ,medicine ,Animals ,Benzothiazoles ,education ,Protein Kinase Inhibitors ,Quizartinib ,education.field_of_study ,Phenylurea Compounds ,Myeloid leukemia ,Cyclin-Dependent Kinase 4 ,Cyclin-Dependent Kinase 6 ,Sorafenib ,medicine.disease ,Tumor Burden ,Leukemia ,Disease Models, Animal ,Leukemia, Myeloid, Acute ,medicine.anatomical_structure ,chemistry ,fms-Like Tyrosine Kinase 3 ,Fms-Like Tyrosine Kinase 3 ,Cancer research ,Signal transduction ,Signal Transduction - Abstract
FLT3ITD subtype acute myeloid leukemia (AML) has a poor prognosis with currently available therapies. A number of small molecule inhibitors of FLT3 and/or CDK4/6 are currently under development. A more complete and quantitative understanding of the mechanisms of actions of FLT3 and CDK4/6 inhibitors may better inform the development of current and future compounds that act on one or both of the molecular targets, and thus may lead to improved treatments for AML. In this study, we investigated in both subcutaneous and orthotopic AML mouse models, the mechanisms of action of three FLT3 and/or CDK4/6 inhibitors: AMG925 (Amgen), sorafenib (Bayer and Onyx), and quizartinib (Ambit Biosciences). A composite model was developed to integrate the plasma pharmacokinetics of these three compounds on their respective molecular targets, the coupling between the target pathways, as well as the resulting effects on tumor burden reduction in the subcutaneous xenograft model. A sequential modeling approach was used, wherein model structures and estimated parameters from upstream processes (e.g. PK, cellular signaling) were fixed for modeling subsequent downstream processes (cellular signaling, tumor burden). Pooled data analysis was employed for the plasma PK and cellular signaling modeling, while population modeling was applied to the subcutaneous and orthotopic tumor burden modeling. The resulting model allows the decomposition of the relative contributions of FLT3ITD and CDK4/6 inhibition on downstream signaling and tumor burden. In addition, the action of AMG925 on cellular signaling and tumor burden was further studied in an orthotopic tumor mouse model more closely representing the physiologically relevant environment for AML.
- Published
- 2014
23. Structure guided design of a series of sphingosine kinase (SphK) inhibitors
- Author
-
Xiaoshan Min, Matthew L. Brown, Yihong Li, Kurt Morgenstern, Brendon Franks, M.J. Schmitt, Richard V. Connors, Timothy J. Carlson, Shyun Li, Xiaodong Wang, Shawn M. Jeffries, Mario G. Cardozo, Matthew H. Plant, Zhulun Wang, Sheere Johnstone, Malgorzata Wanska, Angela Coxon, Alan C. Cheng, Frank Kayser, Darin J. Gustin, Guifen Xu, Nigel Walker, Mariwil Wong, Karen Rex, Joanna Schmitt, Shanling Shen, and Holger Wesche
- Subjects
Gene isoform ,Angiogenesis ,Clinical Biochemistry ,Sphingosine kinase ,Pharmaceutical Science ,Crystallography, X-Ray ,Biochemistry ,Small Molecule Libraries ,chemistry.chemical_compound ,Mice ,Structure-Activity Relationship ,Drug Discovery ,Animals ,Humans ,Protein Isoforms ,Enzyme Inhibitors ,Molecular Biology ,Cells, Cultured ,Sphingosine ,Molecular Structure ,Kinase ,Chemistry ,Organic Chemistry ,Cell migration ,Phenotype ,Cell biology ,Rats ,Enzyme Activation ,Phosphotransferases (Alcohol Group Acceptor) ,Drug Design ,Molecular Medicine ,Structure based - Abstract
Sphingosine-1-phosphate (S1P) signaling plays a vital role in mitogenesis, cell migration and angiogenesis. Sphingosine kinases (SphKs) catalyze a key step in sphingomyelin metabolism that leads to the production of S1P. There are two isoforms of SphK and observations made with SphK deficient mice show the two isoforms can compensate for each other's loss. Thus, inhibition of both isoforms is likely required to block SphK dependent angiogenesis. A structure based approach was used to design and synthesize a series of SphK inhibitors resulting in the identification of the first potent inhibitors of both isoforms of human SphK. Additionally, to our knowledge, this series of inhibitors contains the only sufficiently potent inhibitors of murine SphK1 with suitable physico-chemical properties to pharmacologically interrogate the role of SphK1 in rodent models and to reproduce the phenotype of SphK1 (-/-) mice.
- Published
- 2013
24. Application of automated dried blood spot sampling and LC-MS/MS for pharmacokinetic studies of AMG 517 in rats
- Author
-
Stacy Fide, Craig Uyeda, Kirk Henne, Marcus Soto, Guifen Xu, Philip Wong, Christopher A. James, and Roger Pham
- Subjects
Male ,Bioanalysis ,Clinical Biochemistry ,TRPV Cation Channels ,Context (language use) ,Blood volume ,Pharmacology ,Analytical Chemistry ,Rats, Sprague-Dawley ,Automation ,Pharmacokinetics ,Tandem Mass Spectrometry ,Animals ,Benzothiazoles ,General Pharmacology, Toxicology and Pharmaceutics ,Chromatography, High Pressure Liquid ,Dried Blood Spot Testing ,Chromatography ,Chemistry ,Sampling (statistics) ,General Medicine ,nervous system diseases ,Dried blood spot ,Rats ,Medical Laboratory Technology ,surgical procedures, operative ,Pyrimidines ,nervous system ,therapeutics ,Blood sampling - Abstract
Background: The use of dried blood spot (DBS) sampling technique is of particular interest for drug discovery pharmacokinetic studies due to the small blood volume requirement. In addition, automated blood sampling is an attractive approach for rat pharmacokinetic studies as animal handling work is minimized. The goal of this study was to use an automated DBS sampler for automated blood collection and spotting onto DBS paper for pharmacokinetic studies in rats. AMG 517, a potent and selective vanilloid receptor antagonist, was dosed to rats (n = 3) intravenously and blood samples were collected at nine time points over a 24 h period using the automated DBS sampler. After drying, storage and shipment, the DBS samples were extracted and analyzed by LC–MS/MS. Results: The developed bioanalytical method for the analysis of DBS samples had good accuracy and precision within the context of a discovery, non-GLP analysis. The concentration–time data and pharmacokinetic parameters generated from automated spotted samples were very similar to those derived from manually spotted DBS samples. The manual DBS data were also comparable to plasma data after correction for blood-to-plasma ratio. Conclusion: The automated DBS sampling is a promising technique for rodent pharmacokinetic studies and will improve the efficiency and quality of DBS sampling.
- Published
- 2011
25. Design of 1-piperazinyl-4-arylphthalazines as potent Smoothened antagonists
- Author
-
Randall W. Hungate, Brian Lucas, Hon Chan, Maria M. Toteva, Tom Huang, Dineli Wickramasinghe, Gary Lee, Minqing Rong, Matthew L. Brown, Ben Jiang, Dustin McMinn, Richard J. Austin, Songzhu An, Craig Uyeda, Jacob Kaizerman, Guifen Xu, Wade Aaron, Angela Chong, Qiuping Ye, Wendy Zhong, Jessica Orf, Jay P. Powers, and Michael G. Johnson
- Subjects
Patched ,medicine.medical_specialty ,Clinical Biochemistry ,Pharmaceutical Science ,Administration, Oral ,Biological Availability ,Biochemistry ,Receptors, G-Protein-Coupled ,Mice ,Cytochrome P-450 Enzyme System ,Internal medicine ,Cell Line, Tumor ,Drug Discovery ,medicine ,Animals ,Humans ,Hedgehog Proteins ,Molecular Biology ,Hedgehog ,G protein-coupled receptor ,Cell growth ,Chemistry ,Organic Chemistry ,Smoothened Receptor ,Hedgehog signaling pathway ,Endocrinology ,Drug Design ,Cancer research ,Molecular Medicine ,Phthalazines ,Signal transduction ,Smoothened ,Medulloblastoma ,Signal Transduction - Abstract
The Hedgehog (Hh) signaling pathway regulates cell proliferation and differentiation in developing tissues, and abnormal activation of the Hh pathway has been linked to several tumor subsets. As a transducer of Hh signaling, the GPCR-like protein Smoothened (Smo) is a promising target for disruption of unregulated Hh signaling. A series of 1-amino-4-arylphthalazines was developed as potent and orally bioavailable inhibitors of Smo. A representative compound from this class demonstrated significant tumor volume reduction in a mouse medulloblastoma model.
- Published
- 2010
26. Investigation of collision-induced dissociations involving odd-electron ion formation under positive electrospray ionization conditions using accurate mass
- Author
-
Guifen, Xu, Tom, Huang, Jennifer, Zhang, Jennifer K, Huang, Timothy, Carlson, and Shichang, Miao
- Subjects
Ions ,Spectrometry, Mass, Electrospray Ionization ,Sulfonamides ,Molecular Structure ,Oximes ,Electrons ,Organic Chemicals ,Amides ,Hydrocarbons, Aromatic ,Ethers - Abstract
Collision induced dissociation (CID) has been extensively used for structure elucidation. CID in the electrospray ionization (ESI) and atmospheric pressure chemical ionization (APCI) modes has been found to generate mostly even-electron fragment ions while it has been occasionally reported to form odd-electron free radical ions. However, the structural requirements and the fragmentation mechanisms for free-radical CIDs have not been well characterized in the literature. For this purpose, we studied a series of aromatic and non-aromatic compounds such as sulfonamides, N-aryl amides, tert-butyl-substituted aromatic compounds, aryl alkyl ethers, and O-alkyl aryl oximes using the LTQ and LTQ Orbitrap linear ion trap mass spectrometers. The accurate measurement of the fragment ion masses established the unambiguous assignment of the fragment structures resulting from the test compounds. Our results showed that free radical fragmentation is structure dependent and is to a large extent correlated with the neighboring groups in the structures that stabilize the newly formed free radical ions.
- Published
- 2010
27. Further studies with the 2-amino-1,3-thiazol-4(5H)-one class of 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: reducing pregnane X receptor activity and exploring activity in a monkey pharmacodynamic model
- Author
-
Maury G Emery, Anil S. Guram, Qingyian Liu, Renee Komorowski, Michael Hayashi, Randall W. Hungate, David J. St. Jean, Eric A. Bercot, Nianhe Han, Jiandong Zhang, Qiuping Ye, Rod Cupples, Christopher H. Fotsch, Xiping Zhang, Chester Chenguang Yuan, Guy Matsumoto, Guifen Xu, Jenne Fretland, Michael D. Bartberger, Stefania Ursu, Clarence Hale, Minghan Wang, Hua Tu, Murielle M. Véniant, Dean Hickman, and Michelle Chen
- Subjects
Male ,Models, Molecular ,Receptors, Steroid ,Stereochemistry ,Chemistry, Pharmaceutical ,Molecular Conformation ,Dehydrogenase ,Crystallography, X-Ray ,11β-hydroxysteroid dehydrogenase type 1 ,Oxidoreductase ,Drug Discovery ,11-beta-Hydroxysteroid Dehydrogenase Type 1 ,Animals ,Cytochrome P-450 CYP3A ,Humans ,Tissue Distribution ,Enzyme Inhibitors ,chemistry.chemical_classification ,Pregnane X receptor ,biology ,Pregnane X Receptor ,Cytochrome P450 ,In vitro ,Kinetics ,Macaca fascicularis ,Enzyme ,Nuclear receptor ,chemistry ,Biochemistry ,Drug Design ,biology.protein ,Molecular Medicine - Abstract
A series of compounds containing the 2-amino-1,3-thiazol-4(5H)-one core were found to be potent inhibitors of the enzyme 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1). One of our lead compounds from this series activated the human nuclear xenobiotic receptor, pregnane X receptor (PXR). To try and mitigate the PXR activity, we prepared analogues of our lead series that contained polar groups on the right-hand side of the thiazolone. Several analogues containing amides or alcohols appended to the C-5 position of the thiazolone showed a significant reduction in PXR activity. Through these structure-activity efforts, a compound containing a tert-alcohol group off the C-5 position, analogue (S)-33a, was found to have an 11beta-HSD1 Ki = 35 nM and negligible PXR activity. Compound (S)-33a was advanced into a pharmacodynamic model in cynomolgus monkeys, where it inhibited adipose 11beta-HSD1 activity after being orally administered.
- Published
- 2008
28. A new treatment of organic wastewater with electro—heterocatalysis
- Author
-
Ming Wu, Xue-lin Wang, Long-xiang Tao, Xu Yang, Guifen Xu, and Maosong Xie
- Subjects
Wastewater ,Chemistry ,Biofilter ,Pulp and paper industry - Published
- 2000
- Full Text
- View/download PDF
29. The Oxidative Coupling of Methane and the Aromatization of Methane Without Using Oxidants
- Author
-
A. Parmaliana, A Vaccari, Longxiang Tao, Francesco Frusteri, Xue-lin Wang, Francesco Arena, Xiexian Guo, Xu Yang, WH Chen, Guifen Xu, D Sanfilippo, and Xie
- Subjects
chemistry.chemical_compound ,Natural gas ,business.industry ,Chemistry ,Inorganic chemistry ,Aromatization ,Oxidative coupling of methane ,Coke ,business ,Zeolite ,Benzene ,Methane ,Catalysis - Abstract
It is found that the water in co-feed gas had three kinds of effects on the oxidative coupling of methane : 1) decrease in the temperature of catalyst bed and increase in the selectivity of coupling products 2) a rise in the temperature of catalyst bed 3) oscillating in the temperature of catalyst bed. Those mainly depend on the properties of the catalysts and operation conditions. We have developed the radial flow fixed bed reactor for the oxidative coupling of methane, which may maintain the good performance of catalysts on the larger test scale. It is proposed that the methane aromatization on the Mo/ZSM-5 zeolite catalyst without using oxidants is a structure sensitive reaction and the deactivation of the catalyst is initially related to the reduction of the Mo species at higher valence and loss of surface oxygen. The equation of the coke forming is listed.
- Published
- 1998
- Full Text
- View/download PDF
30. The aromatization of methane over Mo/HZSM-5 zeolites without using oxidants
- Author
-
Xu Yang, Longxiang Tao, Maosong Xie, Xue-lin Wang, Yide Xu, Xie-xian Guo, Ling-sheng Wang, Guifen Xu, Shetian Liu, and Wen-heng Chen
- Subjects
Methane reformer ,Chemistry ,business.industry ,Aromatization ,Methane ,Catalysis ,Liquid fuel ,chemistry.chemical_compound ,Chemical engineering ,Natural gas ,Organic chemistry ,Oxidative coupling of methane ,business ,Zeolite - Abstract
Publisher Summary Methane is the major component of natural gas and its catalytic conversion to desired chemical products or liquid fuel is not only a promising approach for the utilization of natural gas resource but also a great subject to catalysis science that deals with the activation of small molecules. Obviously, direct methane conversion to higher hydrocarbons seems to be one reasonable way to overcome this economic problem. In recent years, the catalytic conversion of methane has been actively studied using dioxygen or other oxidants. The most extensive study has been the oxidative coupling of methane (OCM) since 1982. But the difficulty in meeting the conditions required by the industrial application of the oxidative coupling of methane is still left. Meanwhile, the conversion of methane to benzene over high silica zeolite based catalysts in a pulse-reactor was reported, but limited information was provided. In this chapter the optimizing procedure of methane aromatization over Mo/HZSM-5 is presented and the mechanism for methane activation and aromatization is proposed.
- Published
- 1997
- Full Text
- View/download PDF
31. Sphingosine Kinase Activity Is Not Required for Tumor Cell Viability
- Author
-
Timothy J. Carlson, Astrid Ruefli-Brasse, Elissa Swearingen, Darin J. Gustin, Matthew L. Brown, Paul D. Kassner, Joanna Schmidt, Mariwil Wong, Matthew H. Plant, Karen Rex, Flordeliza Fajardo, Alexander Kamb, Shawn M. Jeffries, Kim Quon, Dineli Wickramasinghe, Zhulun Wang, Shyun Li, Angela Coxon, Yihong Li, Kurt Morgenstern, J. E. Vivienne Watson, Nigel Walker, Brendon Frank, Holger Wesche, and Guifen Xu
- Subjects
Vascular Endothelial Growth Factor A ,Tumor Physiology ,Cell ,Cancer Treatment ,lcsh:Medicine ,Mice ,chemistry.chemical_compound ,Neoplasms ,Molecular Cell Biology ,Basic Cancer Research ,Enzyme Inhibitors ,lcsh:Science ,Tumor Stem Cell Assay ,Multidisciplinary ,Cell Death ,Kinase ,Mechanisms of Signal Transduction ,Tumor Burden ,Cell biology ,Phosphotransferases (Alcohol Group Acceptor) ,SPHK2 ,medicine.anatomical_structure ,Oncology ,Gene Knockdown Techniques ,Medicine ,Female ,RNA Interference ,Cell Division ,Intracellular ,Research Article ,Signal Transduction ,Ceramide ,Cell Survival ,Biology ,Signaling Pathways ,Cell Growth ,Capillary Permeability ,Inhibitory Concentration 50 ,Cell Line, Tumor ,medicine ,Animals ,Humans ,Viability assay ,Sphingosine ,lcsh:R ,Xenograft Model Antitumor Assays ,Sphingolipid ,Enzyme Activation ,chemistry ,lcsh:Q ,Mitogens - Abstract
Sphingosine kinases (SPHKs) are enzymes that phosphorylate the lipid sphingosine, leading to the formation of sphingosine-1-phosphate (S1P). In addition to the well established role of extracellular S1P as a mitogen and potent chemoattractant, SPHK activity has been postulated to be an important intracellular regulator of apoptosis. According to the proposed rheostat theory, SPHK activity shifts the intracellular balance from the pro-apoptotic sphingolipids ceramide and sphingosine to the mitogenic S1P, thereby determining the susceptibility of a cell to apoptotic stress. Despite numerous publications with supporting evidence, a clear experimental confirmation of the impact of this mechanism on tumor cell viability in vitro and in vivo has been hampered by the lack of suitable tool reagents. Utilizing a structure based design approach, we developed potent and specific SPHK1/2 inhibitors. These compounds completely inhibited intracellular S1P production in human cells and attenuated vascular permeability in mice, but did not lead to reduced tumor cell growth in vitro or in vivo. In addition, siRNA experiments targeting either SPHK1 or SPHK2 in a large panel of cell lines failed to demonstrate any statistically significant effects on cell viability. These results show that the SPHK rheostat does not play a major role in tumor cell viability, and that SPHKs might not be attractive targets for pharmacological intervention in the area of oncology.
- Published
- 2013
- Full Text
- View/download PDF
32. Abstract LB-39: Sphingosine kinase activity is not required for tumor cell viability
- Author
-
Holger Wesche, Matthew L. Brown, Timothy J. Carlson, Angela Coxon, Brendon Frank, Darin J. Gustin, Shawn Jeffries, Shyun Li, Yihong Li, Kurt Morgenstern, Matthew Plant, Karen Rex, Joanna Schmidt, Shanling Shen, Nigel Walker, Dineli Wickramasinghe, and Guifen Xu
- Subjects
Cancer Research ,Ceramide ,biology ,Sphingosine ,Kinase ,Cell ,Sphingolipid ,chemistry.chemical_compound ,medicine.anatomical_structure ,Oncology ,chemistry ,Biochemistry ,Apoptosis ,Mitogen-activated protein kinase ,biology.protein ,Cancer research ,medicine ,Intracellular - Abstract
Sphingosine kinase activity is not required for tumor cell viability Holger Wesche, Matthew L. Brown, Timothy J. Carlson, Angela Coxon, Brendon Frank, Darin J. Gustin, Shawn Jeffries, Shyun Li, Yihong Li, Kurt Morgenstern, Matthew Plant, Karen Rex, Joanna Schmidt, Shanling Shen, Nigel Walker, Dineli Wickramasinghe, Mariwil Wong, Guifen Xu Contribution from the Departments of Oncology Research, Medicinal Chemistry, Molecular Structure and Characterization and Pharmacokinetics and Drug Metabolism, Amgen Inc., South San Francisco, 1120 Veterans Blvd., South San Francisco, Ca, 94080. Sphingosine kinases (SPHKs) are enzymes that phosphorylate the lipid sphingosine, leading to the formation of sphingosine-1-phosphate (S1P). In addition to the well established role of extracellular S1P as a mitogen and potent chemoattractant, SPHK activity has been postulated to be an important intracellular regulator of apoptosis. According to the proposed rheostat theory, SPHK activity shifts the intracellular balance from the pro-apoptotic sphingolipids ceramide and sphingosine to the mitogenic S1P, thereby determining the susceptibility of a cell to apoptotic stress. Despite numerous publications with supporting evidence, a clear experimental confirmation of the impact of this mechanism on tumor cell viability in vitro and in vivo has been hampered by the lack of suitable tool reagents. Utilizing a structure based design approach, we developed potent and specific SPHK1/2 inhibitors. These compounds completely inhibited intracellular S1P production in human cells and attenuated vascular permeability in mice, but did not lead to reduced tumor cell growth in vitro or in vivo. These results show that the SPHK rheostat does not play a major role in tumor cell viability, and that SPHK inhibition may not offer an advantage over S1P neutralization in the treatment of cancer. Citation Format: Holger Wesche, Matthew L. Brown, Timothy J. Carlson, Angela Coxon, Brendon Frank, Darin J. Gustin, Shawn Jeffries, Shyun Li, Yihong Li, Kurt Morgenstern, Kurt Morgenstern, Matthew Plant, Karen Rex, Joanna Schmidt, Shanling Shen, Nigel Walker, Dineli Wickramasinghe, Guifen Xu. Sphingosine kinase activity is not required for tumor cell viability. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr LB-39. doi:10.1158/1538-7445.AM2013-LB-39
- Published
- 2013
- Full Text
- View/download PDF
33. Activation and aromatization of methane and ethane overMo(VI)/HZSM-5 and W(VI)/HZSM-5 zeolites catalysts
- Author
-
Longxiang Tao, Maosong Xie, Shetian Liu, Guifen Xu, Yide Xu, and Linsheng Wang
- Subjects
chemistry.chemical_compound ,Chemistry ,High selectivity ,Inorganic chemistry ,Aromatization ,Organic chemistry ,Selectivity ,Zeolite ,Methane ,Catalysis - Abstract
The activation and aromatization of CH4 and C2H6 under non-oxidizing conditionswere investigated over Mo(VI)/HZSM-5 and W(VI)/HZSM-5 zeolite catalysts. Mo(VI)/HZSM-5 exhibits good activity and selectivity for the conversion of CH4 to aromatics, but for C2H6 conversion the catalyst displays high selectivity to CH4. W(VI)/HZSM-5 is inactive for CH4 activation, but exhibits high selectivity for C2H6 aromatization. The W(VI) species can act as a modifier to improve the activity and the stability of Mo(VI)/HZSM-5 for CH4 conversion.
- Published
- 1995
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.